Below are the top 10 Pharmaceutical stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CBP) is on the list.
Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside potential in this segment of the market. Its upside is 354.8%. Its consensus target price is $2.83 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 2nd highest upside potential in this segment of the market. Its upside is 258.9%. Its consensus target price is $3.00 based on the average of all estimates. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has the 3rd highest upside potential in this segment of the market. Its upside is 244.8%. Its consensus target price is $7.00 based on the average of all estimates. PharmAthene, Inc. (AMEX:PIP) has the 4th highest upside potential in this segment of the market. Its upside is 238.5%. Its consensus target price is $11.00 based on the average of all estimates. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has the 5th highest upside potential in this segment of the market. Its upside is 233.3%. Its consensus target price is $8.00 based on the average of all estimates.
China Botanic Pharmaceutical Inc (AMEX:CBP) has the 6th highest upside potential in this segment of the market. Its upside is 205.0%. Its consensus target price is $4.88 based on the average of all estimates. AVANIR Pharmaceuticals (NASDAQ:AVNR) has the 7th highest upside potential in this segment of the market. Its upside is 203.8%. Its consensus target price is $12.00 based on the average of all estimates. GenVec, Inc. (NASDAQ:GNVC) has the 8th highest upside potential in this segment of the market. Its upside is 201.2%. Its consensus target price is $1.13 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 9th highest upside potential in this segment of the market. Its upside is 194.1%. Its consensus target price is $2.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the 10th highest upside potential in this segment of the market. Its upside is 193.3%. Its consensus target price is $8.80 based on the average of all estimates.
Negocioenlinea
tdp2664
China Analyst
Top 10 Pharmaceutical Stocks with Highest Upside: MRNA, CYTR, BSPM, PIP, PRAN, CBP, AVNR, GNVC, EPCT, XOMA (Apr 11, 2011)
No comments:
Post a Comment